| abstract |
The present invention is represented by Formula I as a selective 5-HT 2C receptor gonist for the treatment of disorders associated with 5-HT 2C such as obesity, obsessive compulsive disorder, depression and anxiety 6. It relates to the provision of substituted 2,3,4,5-tetrahydro-1H-benzo [d] azepine. (I) Where R 6 is —NR 10 R 11 , R 10 is a substituted phenylalkyl group or a substituted pyridylalkyl group, and the other substituents are as defined in the specification. |